Status:
COMPLETED
Preventing Intravenous Immunoglobulin-associated Adverse Reactions
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Immunoglobulin Therapy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In patients treated with the monoclonal antibody infliximab (Remicade®) -which binds to and blocks tumor necrosis factor alpha (TNF-alpha) - an infusomat filter is routinely used to prevent the very s...
Detailed Description
Prospective single center study with an observational phase (phase A) and a randomized intervention-phase (phase B), monitoring adverse events and complement activation after IVIG infusion. Patients w...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients at the Division of Hematology at the University Hospital of Basel, Switzerland after allogeneic stem cell transplant and older than 18 years which are planned for at least 2 applications of IVIG. The patients are included in this study only by informed consent.
- Exclusion criteria:
- if inclusion criteria not applicable
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00675805
Start Date
May 1 2008
End Date
December 1 2012
Last Update
September 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Switzerland
Basel, Canton Basel-Town, Switzerland, 4033